Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASC37o
- Development stage
- Preclinical
- Lead developer
- Ascletis Pharma
- Modality
- Peptides
- Administration
- Oral
01
Overview
ASC37o is an orally administered peptide triple agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). Developed by Ascletis (歌礼生物科技), the drug is currently in the discovery phase for the treatment of obesity. By simultaneously activating these three metabolic pathways, ASC37o is designed to achieve superior weight loss and metabolic benefits compared to single or dual agonists. The oral peptide formulation aims to provide a more convenient alternative to injectable therapies in the incretin class, potentially improving patient adherence and accessibility.
- Other names
- ASC37oASC-37oASC 37o
02
Targets
Beyond the preview
Go deeper on ASC37o.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASC37o.